Clinical

Patients who have migraine often suffer from coexisting issues, such as sleep difficulties, vertigo, and dizziness. A study evaluating the presence of certain symptoms in patients with migraine indicated that some may have a common pathophysiology.

There have been few therapeutic options for treating thrombocytopenia in MDS patients. Now, early phase data suggest that CC-486 (oral azacytidine, an investigational drug sponsored by Celgene) is a relatively safe and effective treatment for thrombocytopenic patients with MDS.

A new investigational drug has demonstrated high response rates in patients with a rare but highly aggressive blood disease that currently has no approved therapies, according to new research led by investigators at The University of Texas MD Anderson Cancer Center.